Neurodegeneration as a Tractable Target

The Alzheimer’s field has produced the first generation of diseasemodifying anti-amyloid therapeutics. The next generation will be combinations — antiamyloid plus anti-tau, plus neuroinflammation control, plus the latent-virus eradication patterns now strongly implicated in neurodegeneration. The CureForge Alzheimer’s Disease Institute is the federation’s research engine for that work. Twelve specialized AI systems collaborate across amyloid-beta modulator design, tau modulator design, neuroinflammation pathway intervention, viral-neurodegeneration biology coordinated with the federation’s infectious disease institute, brain MRI biomarker extraction, brain PET imaging, glymphatic clearance modeling, cognitive trajectory tracking, and adversarial review of every Alzheimer’s-related claim before publication. Every clinical recommendation is reviewed by qualified neurologists.

Value proposition:

• Multi-mechanism Alzheimer’s therapeutic design
• Neuroimaging biomarkers calibrated across population-scale Alzheimer’s cohorts
• Federated cohort coordination for cross-population validation